Company news: Roche, MRM, McKesson

Share this article:
Roche's latest real estate deal is putting the drug maker on both sides of the New York-New Jersey divide. The company announced Thursday that it was establishing a research division in Manhattan, and taking with it some of the responsibilities and 200 employees that were part of the Nutley, NJ site that is set to close, reported the New York Times. The Swiss company is still going to keep 50 management-level jobs in New Jersey, the Times noted.

MRM worldwide also announced a location change Thursday. The digital agency will open the doors to its new Princeton, NJ, office September 24. The move includes an open floor plan “to foster community and creativity,” as well as a collaborative space dubbed Einstein's Attic, which gives clients and creatives space to test out different technologies.

Arizona Attorney General Tom Horne is suing drug wholesaler McKesson over price inflation, reported the Associated Press. The suit accuses the wholesaler of marking up the cost of drugs including Allegra, Celebrex, Coumadin, Flonase, Lipitor and Valium. The lawsuit alleges that the markup was passed along to third-party payers and consumers and seeks civil penalties of up to $10,000 per violation as well as restitution. Kentucky's Attorney General Jack Conway filed a pricing lawsuit against McKesson last year.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.